Roche’s ipatasertib combo shows early promise in triple-negative breast cancer
The results showed a 73% overall response rate irrespective of PD-L1 status.
Read More
Tag: PD-L1 status
- Liverpool and McMaster University announce £300,000 strategic research partnership
- Study finds link between malaria parasites developing antimalarial drug resistance
- Researchers develop ‘digital twin’ heart models to better monitor PAH NHS patients
- Closed Loop and Pharmanovia investigate precision medicine combination in hypertension
- US study reveals interferon combinations cause lupus symptoms and affect treatment
